Cenobamate: clinical trials recruiting now
3
Recruiting trials
4
Conditions studied
0
US states with sites
2
Countries
FDA drug label
- FDA-approved
- Yes. Cenobamate appears in the FDA drug-label database. Marketed as Xcopri, Xcopri Maintenance Pack, Xcopri Titration Pack.
- Mechanism of action
- Sodium Channel Antagonists; GABA A Receptor Positive Modulators; Cytochrome P450 2B6 Inhibitors; Cytochrome P450 2C19 Inhibitors; Cytochrome P450 3A Inhibitors; Cytochrome P450 2B6 Inducers; Cytochrome P450 2C8 Inducers; Cytochrome P450 3A4 Inducers (as stated on the FDA label)
FDA-approved use
XCOPRI is indicated for the treatment of partial-onset seizures in adult patients. XCOPRI is indicated for the treatment of partial-onset seizures in adult patients. ( 1 )
Phase breakdown
Phase 2 1
Phase 3 1
Not applicable 1
Conditions being studied
| Condition | Trials |
|---|---|
| Epilepsy · Cenobamate for Epilepsy | 3 |
| Epilepsies, Partial | 1 |
| Epilepsy, Generalized | 1 |
| Focal Epilepsy With and Without Secondary Generalization | 1 |
Recruiting trials involving Cenobamate
- ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.
- Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spain
- Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures
Common questions
Is Cenobamate FDA-approved?
Yes, marketed as Xcopri, Xcopri Maintenance Pack, Xcopri Titration Pack.
How many recruiting trials involve Cenobamate?
3 recruiting trials across 4 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.